谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

Yosuke Kawashima,Tatsuro Fukuhara,Haruhiro Saito,Naoki Furuya,Kana Watanabe,Shunichi Sugawara,Shunichiro Iwasawa,Yoshio Tsunezuka,Ou Yamaguchi,Morihito Okada,Kozo Yoshimori,Ichiro Nakachi,Masahiro Seike,Koichi Azuma,Futoshi Kurimoto,Yukari Tsubata,Yuka Fujita,Hiromi Nagashima,Gyo Asai,Satoshi Watanabe,Masaki Miyazaki,Koichi Hagiwara,Toshihiro Nukiwa,Satoshi Morita,Kunihiko Kobayashi,Makoto Maemondo

The Lancet Respiratory Medicine（2022）

引用 57|浏览50
暂无评分
摘要
Chugai Pharmaceutical.
更多
查看译文
关键词
non-small-cell non-small-cell lung cancer,lung cancer,erlotinib,bevacizumab,egfr-mutant,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要